Cytiva announced on Jan. 16, 2025 that it has teamed up with Cellular Origins, a TTP company based in the UK that specializes in advancing scalable and cost-effective cell and gene therapy (CGT) manufacturing, to combine technology platforms that will offer automated, robotic manufacturing of CGTs. Through the collaboration, Cytiva’s automated Sefia platform will be combined with Cellular Origin’s Constellation, an automated robotic platform. The integration of these technologies is aimed at enabling scale-up of CGT manufacturing to industrial levels without changing the initial manufacturing process used during discovery phases or clinical trials, according to a company press release .
